---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066366"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:42:55.199711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio Q1 net loss $11.0M; cash $65.5M, runs into 2H'26; first patient dosed in Phase 2a Part B for AA

## Summary
- Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).
- Cash and equivalents $65.5M as of March 31, 2025; expected to fund operations into 2H'26.
- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data expected 1H'26.
- Fast Track designation granted to bempikibart for alopecia areata; durable responses seen in late-breaking AAD presentation.
- First patient dosed in Part A open-label extension; median follow-up 41 weeks shows maintenance or further hair growth.

## SEC filing metadata
- accession: 0000950170-25-066366
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000095017025066366/0000950170-25-066366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000095017025066366/qttb-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066366
- JSON: https://secwatch.observer/filing/0000950170-25-066366.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.